Climb Bio/$CLYM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Ticker
$CLYM
Sector
Primary listing
Employees
29
Headquarters
Website
Climb Bio Metrics
BasicAdvanced
$292M
-
-$0.90
-0.24
-
Price and volume
Market cap
$292M
Beta
-0.24
52-week high
$8.04
52-week low
$1.05
Average daily volume
616K
Financial strength
Current ratio
15.156
Quick ratio
14.473
Long term debt to equity
0.178
Total debt to equity
0.337
Profitability
EBITDA (TTM)
-67.786
Management effectiveness
Return on assets (TTM)
-22.04%
Return on equity (TTM)
-32.15%
Valuation
Price to book
1.82
Price to tangible book (TTM)
1.82
Price to free cash flow (TTM)
-7.471
Free cash flow yield (TTM)
-13.38%
Free cash flow per share (TTM)
-0.818
Growth
Earnings per share change (TTM)
-41.51%
3-year earnings per share growth (CAGR)
-19.50%
What the Analysts think about Climb Bio
Analyst ratings (Buy, Hold, Sell) for Climb Bio stock.
Climb Bio Financial Performance
Revenues and expenses
Climb Bio Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Climb Bio stock?
Climb Bio (CLYM) has a market cap of $292M as of March 21, 2026.
What is the P/E ratio for Climb Bio stock?
The price to earnings (P/E) ratio for Climb Bio (CLYM) stock is 0 as of March 21, 2026.
Does Climb Bio stock pay dividends?
No, Climb Bio (CLYM) stock does not pay dividends to its shareholders as of March 21, 2026.
When is the next Climb Bio dividend payment date?
Climb Bio (CLYM) stock does not pay dividends to its shareholders.
What is the beta indicator for Climb Bio?
Climb Bio (CLYM) has a beta rating of -0.24. This means that it has an inverse relation to market volatility.